Literature DB >> 782834

Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.

R M Pinder, R N Brogden, P R Sawyer, T M Speight, G S Avery.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 782834     DOI： 10.2165/00003495-197611050-00001

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  105 in total

1.  Editorial: Long-term assessment of levodopa therapy in Parkinson's disease.

Authors:  A Barbeau
Journal:  Can Med Assoc J       Date:  1975-06-21       Impact factor: 8.262

2.  Studies on the antiparkinsonism efficacy of lergotrile.

Authors:  A Lieberman; T Miyamoto; A F Battista; M Goldstein
Journal:  Neurology       Date:  1975-05       Impact factor: 9.910

3.  [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].

Authors:  A Stammler; K Vielhaber
Journal:  Fortschr Neurol Psychiatr Grenzgeb       Date:  1972-10

4.  Bromocriptine in Parkinsonism.

Authors:  D B Calne; P F Teychenne; L E Claveria; R Eastman; J K Greenacre; A Petrie
Journal:  Br Med J       Date:  1974-11-23

5.  [The capillary enzyme barrier for DOPA at the level of some brain stem nuclei in the rat].

Authors:  J Constantinidis; G Bartholini; F Geissbühler; R Tissot
Journal:  Experientia       Date:  1970-04-15

6.  The Eaton Collaborative Study of levodopa therapy in parkinsonism: a summary.

Authors:  R E Keenan
Journal:  Neurology       Date:  1970-12       Impact factor: 9.910

7.  Alpha methyldopahydrazine as an adjunct to levodopa therapy in Parkinson's disease.

Authors:  D W Paty; N Jaatoul; A Kertesz; W McInnis
Journal:  Can J Neurol Sci       Date:  1975-08       Impact factor: 2.104

8.  Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.

Authors:  C D Marsden; P E Barry; J D Parkes; K J Zilkha
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-02       Impact factor: 10.154

9.  [L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor].

Authors:  J Görlich; E Markus
Journal:  Dtsch Med Wochenschr       Date:  1972-08-25       Impact factor: 0.628

10.  Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.

Authors:  C J Andrews; B Somerville
Journal:  Med J Aust       Date:  1974-03-23       Impact factor: 7.738
View more
  14 in total

1.  Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease.

Authors:  M Contin; R Riva; P Martinelli; F Albani; A Baruzzi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  The influence of levodopa on gastric emptying in man.

Authors:  D R Robertson; A G Renwick; N D Wood; N Cross; B S Macklin; J S Fleming; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

3.  Effect of L-dopa on visual evoked potentials and neuropsychological tests in adult phenylketonuria patients.

Authors:  K Ullrich; J Weglage; C Oberwittler; M Pietsch; B Fünders; H von Eckardstein; J P Colombo
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

4.  The effect of benserazide on the peripheral and central distribution and metabolism of levodopa after acute and chronic administration in the rat.

Authors:  A P Kent; G M Stern; R A Webster
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

5.  The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa.

Authors:  D R Robertson; N D Wood; H Everest; K Monks; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

6.  Effect of L-dopa on pattern visual evoked potentials (P-100) and neuropsychological tests in untreated adult patients with phenylketonuria.

Authors:  K Ullrich; J Weglage; C Oberwittler; M Pietsch; B Fünders; H van Eckhardstein; J P Colombo
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

Review 7.  A risk-benefit assessment of drugs used in the management of Parkinson's disease.

Authors:  I Y Bodagh; D R Robertson
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

Review 8.  Fixed combination drug therapy.

Authors:  G M Shenfield
Journal:  Drugs       Date:  1982-06       Impact factor: 9.546

9.  Intestinal absorption of levodopa in man.

Authors:  U Gundert-Remy; R Hildebrandt; A Stiehl; E Weber; G Zürcher; M Da Prada
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  The comparative long-term effects of ciladopa (AY-27,110), a chemically novel dopaminergic agonist, in 6-OHDA-lesioned and intact rats.

Authors:  K Voith
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.